Extended Data Fig. 7: Loss of Irg1 enhances the efficacy of anti-PD-1 immune checkpoint blockade.
From: Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth
(A) Depletion of CD8 + T cells restored D4M3A tumor growth in Irg1-/- mice (n = 7 mice). P value were calculated by two-sided Tukey’s multiple comparisons test. (B) Spider plot of D4M3A syngeneic tumors grown in WT and Irg1-/- mice and treated with anti-PD-1 or isotype control IgG (n = 6 mice). (C-F) Expression of IL6 (C), TGFβ1(D), CXCL10 (E) and IL10 (F) in D4M3A tumor tissues from WT and Irg1-/- mice that were treated with anti-PD-1 or isotype control IgG (n = 5 biologically independent samples). For all panels, data are represented as mean ± SEM.
